drugset / Trial / NCT04167618
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
NaSingle-groupOpen-labelTreatment
Summary
Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2022-08-11
- Completion
- 2022-08-11
Outcome
Outcome not reported
Stopped (Business): “Business priorities”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DTPA-omburtamab | Monoclonal antibody | — | Other |